$RHE
Regional Health Properties Inc

2024 Q1 Form 10-K Financial Statement

#000095017024039414 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $4.127M $4.522M $17.16M
YoY Change 5.66% -55.47% -52.22%
Cost Of Revenue $2.101M $2.190M $9.200M
YoY Change -17.19% -65.85% -55.02%
Gross Profit $2.026M $2.332M $7.964M
YoY Change 47.99% -37.68% -48.53%
Gross Profit Margin 49.09% 51.57% 46.4%
Selling, General & Admin $1.809M $1.968M $6.315M
YoY Change 19.64% -27.25% -58.08%
% of Gross Profit 89.29% 84.39% 79.29%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $511.0K $517.0K $2.255M
YoY Change 0.2% -11.62% -6.2%
% of Gross Profit 25.22% 22.17% 28.31%
Operating Expenses $4.421M $2.172M $17.97M
YoY Change -4.95% -43.66% -57.97%
Operating Profit -$294.0K $160.0K -$804.0K
YoY Change -60.54% -241.59% -88.21%
Interest Expense $674.0K -$685.0K $2.751M
YoY Change -0.88% 1.63% 8.78%
% of Operating Profit -428.13%
Other Income/Expense, Net -$668.0K $287.0K -$3.084M
YoY Change -46.43% -84.47% 6753.33%
Pretax Income -$962.0K -$238.0K -$3.888M
YoY Change -51.71% -89.39% -43.38%
Income Tax
% Of Pretax Income
Net Earnings -$962.0K -$238.0K -$3.888M
YoY Change -51.71% -94.7% -43.38%
Net Earnings / Revenue -23.31% -5.26% -22.65%
Basic Earnings Per Share -$0.52 $21.05
Diluted Earnings Per Share -$0.52 -$0.13 $21.05
COMMON SHARES
Basic Shares Outstanding 1.839M 1.883M 1.877M
Diluted Shares Outstanding 1.839M 1.877M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $752.0K $953.0K $953.0K
YoY Change -73.17% 13.05% 13.05%
Cash & Equivalents $800.0K $1.000M $953.0K
Short-Term Investments
Other Short-Term Assets $410.0K $609.0K $609.0K
YoY Change -88.32% -84.02% -84.02%
Inventory
Prepaid Expenses
Receivables $1.464M $1.403M $1.403M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.626M $2.965M $2.965M
YoY Change -73.83% -75.38% -75.38%
LONG-TERM ASSETS
Property, Plant & Equipment $44.89M $45.34M $47.89M
YoY Change -2.65% -2.73% -3.17%
Goodwill $1.585M $1.585M
YoY Change 0.0% 0.0%
Intangibles $11.73M $11.84M
YoY Change -3.58% -3.57%
Long-Term Investments
YoY Change
Other Assets $3.223M $3.231M $3.231M
YoY Change
Total Long-Term Assets $58.60M $59.22M $59.22M
YoY Change 4.79% 4.74% 4.74%
TOTAL ASSETS
Total Short-Term Assets $2.626M $2.965M $2.965M
Total Long-Term Assets $58.60M $59.22M $59.22M
Total Assets $61.23M $62.18M $62.18M
YoY Change -7.17% -9.33% -9.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.106M $2.493M $2.493M
YoY Change -1.68% -24.29% -24.29%
Accrued Expenses $7.047M $6.977M $6.977M
YoY Change 34.13% 38.54% 38.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.15M $9.470M $9.470M
YoY Change 20.68% 13.7% 13.7%
LONG-TERM LIABILITIES
Long-Term Debt $50.01M $50.74M $50.74M
YoY Change -2.92% -2.77% -2.77%
Other Long-Term Liabilities $1.797M $1.791M $1.791M
YoY Change -57.44% -58.89% -58.89%
Total Long-Term Liabilities $50.01M $50.74M $52.53M
YoY Change -2.92% -2.77% -7.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.15M $9.470M $9.470M
Total Long-Term Liabilities $50.01M $50.74M $52.53M
Total Liabilities $61.96M $62.00M $62.00M
YoY Change -3.41% -4.42% -4.42%
SHAREHOLDERS EQUITY
Retained Earnings -$82.86M -$81.90M
YoY Change -32.85% -32.54%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$734.0K $185.0K $185.0K
YoY Change
Total Liabilities & Shareholders Equity $61.23M $62.18M $62.18M
YoY Change -7.17% -9.33% -9.33%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$962.0K -$238.0K -$3.888M
YoY Change -51.71% -94.7% -43.38%
Depreciation, Depletion And Amortization $511.0K $517.0K $2.255M
YoY Change 0.2% -11.62% -6.2%
Cash From Operating Activities $600.0K $252.0K $3.700M
YoY Change -76.92% -117.68% -202.89%
INVESTING ACTIVITIES
Capital Expenditures $55.00K $42.00K $958.0K
YoY Change 2650.0% -57.14% 240.93%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$55.00K -$42.00K -$958.0K
YoY Change 2650.0% -57.14% 240.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -751.0K -661.0K -2.479M
YoY Change 9.64% -1988.57% 20.22%
NET CHANGE
Cash From Operating Activities 600.0K 252.0K 3.700M
Cash From Investing Activities -55.00K -42.00K -958.0K
Cash From Financing Activities -751.0K -661.0K -2.479M
Net Change In Cash -209.0K -451.0K 275.0K
YoY Change -110.94% -69.69% -104.63%
FREE CASH FLOW
Cash From Operating Activities $600.0K $252.0K $3.700M
Capital Expenditures $55.00K $42.00K $958.0K
Free Cash Flow $545.0K $210.0K $2.742M
YoY Change -79.02% -113.79% -170.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Lessor Operating Lease Existence Of Option To Extend
LessorOperatingLeaseExistenceOfOptionToExtend
true
CY2020 us-gaap Lessor Operating Lease Existence Of Option To Extend
LessorOperatingLeaseExistenceOfOptionToExtend
true
CY2018Q4 us-gaap Lessor Operating Lease Existence Of Option To Extend
LessorOperatingLeaseExistenceOfOptionToExtend
true
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2018Q4 us-gaap Lessor Operating Lease Existence Of Option To Extend
LessorOperatingLeaseExistenceOfOptionToExtend
true
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001004724
CY2018Q4 us-gaap Lessor Operating Lease Existence Of Option To Extend
LessorOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-33135
CY2023 dei Entity Registrant Name
EntityRegistrantName
Regional Health Properties, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
GA
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5166048
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1050 Crown Pointe Parkway
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30338
CY2023 dei City Area Code
CityAreaCode
678
CY2023 dei Local Phone Number
LocalPhoneNumber
869-5116
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5980720
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1839028
CY2023 dei Auditor Firm
AuditorFirmId
677
CY2023 dei Auditor Name
AuditorName
Cherry Bekaert LLP
CY2023 dei Auditor Location
AuditorLocation
Atlanta, Georgia
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
45337000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46611000
CY2023Q4 us-gaap Cash
Cash
953000
CY2022Q4 us-gaap Cash
Cash
843000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
3231000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3066000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2040000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1298000
CY2023Q4 us-gaap Receivables From Customers
ReceivablesFromCustomers
1403000
CY2022Q4 us-gaap Receivables From Customers
ReceivablesFromCustomers
6289000
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
609000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
746000
CY2023Q4 us-gaap Notes Receivable Net
NotesReceivableNet
1044000
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
1099000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2471000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2471000
CY2023Q4 rhe Finite Lived Intangible Assets Lease Rights Net
FiniteLivedIntangibleAssetsLeaseRightsNet
87000
CY2022Q4 rhe Finite Lived Intangible Assets Lease Rights Net
FiniteLivedIntangibleAssetsLeaseRightsNet
110000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2556000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2848000
CY2023Q4 us-gaap Goodwill
Goodwill
1585000
CY2022Q4 us-gaap Goodwill
Goodwill
1585000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
4000
CY2023Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2901000
CY2022Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
2912000
CY2023Q4 us-gaap Assets
Assets
62181000
CY2022Q4 us-gaap Assets
Assets
68580000
CY2023Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
43855000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
45163000
CY2023Q4 us-gaap Longterm Transition Bond Current And Noncurrent
LongtermTransitionBondCurrentAndNoncurrent
5991000
CY2022Q4 us-gaap Longterm Transition Bond Current And Noncurrent
LongtermTransitionBondCurrentAndNoncurrent
6120000
CY2023Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
889000
CY2022Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
895000
CY2023Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
2493000
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3293000
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
4060000
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
5036000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2917000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3226000
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
1791000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
1131000
CY2023Q4 us-gaap Liabilities
Liabilities
61996000
CY2022Q4 us-gaap Liabilities
Liabilities
64864000
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1850000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1793000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1839000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1784000
CY2023Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
63059000
CY2022Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
62702000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81902000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121409000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
185000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3716000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62181000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68580000
CY2023 us-gaap Revenues
Revenues
17164000
CY2022 us-gaap Revenues
Revenues
35925000
CY2023 rhe Patient Care Expense
PatientCareExpense
9200000
CY2022 rhe Patient Care Expense
PatientCareExpense
20453000
CY2023 rhe Facility Rent Expense
FacilityRentExpense
594000
CY2022 rhe Facility Rent Expense
FacilityRentExpense
4876000
CY2023 rhe Cost Of Management Fees
CostOfManagementFees
595000
CY2022 rhe Cost Of Management Fees
CostOfManagementFees
619000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2255000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2404000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3976000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4652000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1150000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4916000
CY2022 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-1417000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-1436000
CY2023 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
198000
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1974000
CY2023 us-gaap Operating Expenses
OperatingExpenses
17968000
CY2022 us-gaap Operating Expenses
OperatingExpenses
42747000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-804000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-6822000
CY2023 us-gaap Interest Expense
InterestExpense
2751000
CY2022 us-gaap Interest Expense
InterestExpense
2529000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
452000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-333000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2936000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3084000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-45000
CY2023 us-gaap Profit Loss
ProfitLoss
-3888000
CY2022 us-gaap Profit Loss
ProfitLoss
-6867000
CY2022 rhe Preferred Stock Dividends Undeclared
PreferredStockDividendsUndeclared
8997000
CY2023 rhe Preferred Stock Dividends Gain On Extinguishment
PreferredStockDividendsGainOnExtinguishment
43395000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
39507000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15864000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
21.05
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.93
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
21.05
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.93
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1877000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1776000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1877000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1776000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10396000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
233000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-46000
CY2022 us-gaap Profit Loss
ProfitLoss
-6867000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3716000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
357000
CY2023 rhe Extinguishment Of Preferred Stock Value
ExtinguishmentOfPreferredStockValue
-61997000
CY2023 rhe Adjustment Of Exchange Of Preferred Stock Value
AdjustmentOfExchangeOfPreferredStockValue
61997000
CY2023 us-gaap Profit Loss
ProfitLoss
-3888000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
185000
CY2023 us-gaap Profit Loss
ProfitLoss
-3888000
CY2022 us-gaap Profit Loss
ProfitLoss
-6867000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2255000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2404000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
357000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
233000
CY2023 rhe Rent Expense Less Than In Excess Of Cash Paid
RentExpenseLessThanInExcessOfCashPaid
-17000
CY2022 rhe Rent Expense Less Than In Excess Of Cash Paid
RentExpenseLessThanInExcessOfCashPaid
122000
CY2023 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
199000
CY2022 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-425000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
75000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
86000
CY2022 rhe Noncash Gains Losses On Extinguishment Of Debt
NoncashGainsLossesOnExtinguishmentOfDebt
-452000
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1417000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
-1436000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1150000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4916000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3545000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6677000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1152000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-197000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1776000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-393000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
660000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-497000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3712000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3596000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
958000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
281000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-958000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-281000
CY2022 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
7778000
CY2023 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1357000
CY2022 us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
8830000
CY2023 rhe Deferred Financing Costs
DeferredFinancingCosts
17000
CY2022 rhe Deferred Financing Costs
DeferredFinancingCosts
296000
CY2023 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
1105000
CY2022 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
718000
CY2022 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
50000
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
46000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2479000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2062000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
275000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5939000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9848000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4184000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
2668000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2445000
CY2023 rhe Reclassification From Accounts Receivable To Notes Receivable
ReclassificationFromAccountsReceivableToNotesReceivable
312000
CY2022 rhe Reclassification From Accounts Receivable To Notes Receivable
ReclassificationFromAccountsReceivableToNotesReceivable
546000
CY2023 rhe Exchange Of Preferred Stock Series A To Series B
ExchangeOfPreferredStockSeriesAToSeriesB
18602000
CY2023 rhe Preferred Stock Dividends Gain On Extinguishment
PreferredStockDividendsGainOnExtinguishment
43395000
CY2023 rhe Vendor Financed Insurance
VendorFinancedInsurance
1170000
CY2022 rhe Vendor Financed Insurance
VendorFinancedInsurance
1259000
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported results of operations during the reporting period. Significant estimates include the self-insurance reserve for professional and general liability, patient care revenues, allowance for doubtful accounts and credit losses, contractual allowances for Medicaid, Medicare, and managed care reimbursements, deferred tax valuation allowance, valuation of goodwill and other long-lived assets, and cash flow projections. Actual results could differ materially from those estimates.</span></p>
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain reclassifications have been made to the amounts in prior periods in order to conform to the current period's presentation. These classifications had no impact on net loss or cash flows from operations for the year ended 2023 or 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023 rhe Percentage Of Revenue Recognized From Government Sources
PercentageOfRevenueRecognizedFromGovernmentSources
0.90
CY2023Q4 rhe Penalty For Service Contract Non Performance
PenaltyForServiceContractNonPerformance
50000
CY2023Q4 rhe Percentage Of Reserve For Patient Care Receivables
PercentageOfReserveForPatientCareReceivables
0.015
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1400000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6300000
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
3443000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7587000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2040000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1298000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1403000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6289000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially expose the Company to concentrations of credit risk consist primarily of cash, restricted cash, accounts receivable and straight-line rent receivables. Cash and restricted cash are held with various financial institutions. From time to time, these balances exceed the federally insured limits. These balances are maintained with high quality financial institutions which management believes limits the risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable are recorded at net realizable value. The Company performs ongoing evaluations of its tenants and significant third-party payors with which it contracts, and generally does not require collateral. The Company maintains an allowance for doubtful accounts and credit losses which management believes is sufficient to cover potential losses. Delinquent accounts receivable are charged against the allowance for doubtful accounts and credit losses once collection has been determined to be unlikely. Accounts receivable are considered past due and placed on delinquent status based upon contractual terms as well as how frequently payments are received, on an individual account basis.</span></p>
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
600000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
700000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2023 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
336000
CY2022 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
391000
CY2023 us-gaap Real Estate Tax Expense
RealEstateTaxExpense
336000
CY2022 us-gaap Real Estate Tax Expense
RealEstateTaxExpense
391000
CY2023Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
2493000
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3293000
CY2023Q4 us-gaap Other Liabilities
OtherLiabilities
1800000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
1100000
CY2023Q4 us-gaap Lease Deposit Liability
LeaseDepositLiability
700000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
48000
CY2023Q4 rhe Antidilutive Securities Excluded From Computation Of Earnings Per Share Intrinsic Value
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareIntrinsicValue
0
CY2023 us-gaap Other Expenses
OtherExpenses
900000
CY2022 us-gaap Other Expenses
OtherExpenses
1300000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1000000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3700000
CY2023 rhe Accumulated And Unpaid Dividends On Series A Preferred Stock
AccumulatedAndUnpaidDividendsOnSeriesAPreferredStock
50400000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
50700000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
1100000
CY2023Q4 rhe Long Term Debt Maturities Repayments Of Principal In Next Twelve Months Subject To Non Default In Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsSubjectToNonDefaultInPayments
1900000
CY2023 us-gaap Short Term Debt Refinanced Amount
ShortTermDebtRefinancedAmount
0
CY2022Q4 rhe Number Of Skilled Nursing Facilities
NumberOfSkilledNursingFacilities
3
CY2023 rhe Debt Modification
DebtModification
0
CY2022Q4 rhe Number Of Facilities
NumberOfFacilities
5
CY2023Q4 us-gaap Cash
Cash
953000
CY2022Q4 us-gaap Cash
Cash
843000
CY2023Q4 rhe Pledged Assets Not Separately Reported Other Financial Instrument
PledgedAssetsNotSeparatelyReportedOtherFinancialInstrument
159000
CY2022Q4 rhe Pledged Assets Not Separately Reported Other Financial Instrument
PledgedAssetsNotSeparatelyReportedOtherFinancialInstrument
135000
CY2023Q4 us-gaap Replacement Reserve Escrow
ReplacementReserveEscrow
2125000
CY2022Q4 us-gaap Replacement Reserve Escrow
ReplacementReserveEscrow
2155000
CY2023Q4 us-gaap Escrow Deposit
EscrowDeposit
630000
CY2022Q4 us-gaap Escrow Deposit
EscrowDeposit
459000
CY2023Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
317000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
317000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
3231000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3066000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4184000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3909000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68408000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68327000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23071000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21716000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
45337000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46611000
CY2023Q4 us-gaap Land Improvements
LandImprovements
100000
CY2023 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2022 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2023 us-gaap Depreciation
Depreciation
1817000
CY2022 us-gaap Depreciation
Depreciation
1966000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
438000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
438000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2255000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2404000
CY2022Q4 rhe Finite And Indefinite Lived Intangible Assets Gross
FiniteAndIndefiniteLivedIntangibleAssetsGross
16953000
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
1585000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4679000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12274000
CY2022Q4 us-gaap Goodwill
Goodwill
1585000
CY2023Q4 rhe Finite And Indefinite Lived Intangible Assets Gross
FiniteAndIndefiniteLivedIntangibleAssetsGross
16923000
CY2023Q4 us-gaap Goodwill Gross
GoodwillGross
1585000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5086000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11837000
CY2023Q4 us-gaap Goodwill
Goodwill
1585000
CY2022 rhe Operating Leases Number Of Skilled Nursing Facilities Leased
OperatingLeasesNumberOfSkilledNursingFacilitiesLeased
9
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments Due Year One
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearOne
678000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year One
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearOne
29000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
649000
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Two
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearTwo
672000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Two
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearTwo
77000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
595000
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Three
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearThree
658000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Three
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearThree
120000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
538000
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Four
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearFour
671000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Four
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearFour
165000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
506000
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments Due Year Five
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueYearFive
685000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability Due Year Five
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueYearFive
208000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
477000
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments Due After Year Five
LesseeOperatingLeaseLiabilityFutureRentalPaymentsDueAfterYearFive
230000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability Due After Year Five
LesseeOperatingLeaseAccretionOfLeaseLiabilityDueAfterYearFive
78000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
152000
CY2023Q4 rhe Lessee Operating Lease Liability Future Rental Payments
LesseeOperatingLeaseLiabilityFutureRentalPayments
3594000
CY2023Q4 rhe Lessee Operating Lease Accretion Of Lease Liability
LesseeOperatingLeaseAccretionOfLeaseLiability
677000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2917000
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0798
CY2023Q3 rhe Lease Amendment Decrease In Monthly Rent
LeaseAmendmentDecreaseInMonthlyRent
43000000
CY2023Q3 rhe Lease Amendment Included Promissory Note
LeaseAmendmentIncludedPromissoryNote
312000000
CY2023Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
304000000
CY2022 rhe Number Of Leased Or Subleased Facilities
NumberOfLeasedOrSubleasedFacilities
20
CY2022 rhe Operating Leases Number Of Skilled Nursing Facilities Sub Leased
OperatingLeasesNumberOfSkilledNursingFacilitiesSubLeased
8
CY2023 rhe Number Of Leased Or Subleased Facilities
NumberOfLeasedOrSubleasedFacilities
11
CY2023 rhe Number Of Managed Skilled Nursing Facilities
NumberOfManagedSkilledNursingFacilities
8
CY2023 rhe Weighted Average Remaining Lease Term Facilities Lessor
WeightedAverageRemainingLeaseTermFacilitiesLessor
P5Y6M
CY2018Q4 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
Each sublease has an initial term of 10 years, with renewal options
CY2018Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P10Y
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
6559000
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
6666000
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
6771000
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
6879000
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Five Years
LessorOperatingLeasePaymentsToBeReceivedFiveYears
6730000
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received Thereafter
LessorOperatingLeasePaymentsToBeReceivedThereafter
8227000
CY2023Q4 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
41832000
CY2022Q4 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
7075000
CY2023Q4 rhe Accrued Payroll Related Expenses Current
AccruedPayrollRelatedExpensesCurrent
255000
CY2022Q4 rhe Accrued Payroll Related Expenses Current
AccruedPayrollRelatedExpensesCurrent
539000
CY2023Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
3077000
CY2022Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
2428000
CY2023Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
61000
CY2022Q4 us-gaap Self Insurance Reserve Current
SelfInsuranceReserveCurrent
80000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
225000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
210000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
43000
CY2022Q4 rhe Medicaid Overpayment Healthcare Services
MedicaidOverpaymentHealthcareServices
169000
CY2023Q4 rhe Insurance Escrow Current
InsuranceEscrowCurrent
98000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
344000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1567000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4060000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5036000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
51802000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
53302000
CY2023Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
954000
CY2022Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
1005000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
113000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
119000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
50735000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52178000
CY2023Q4 rhe Debt Instrument Number Of Credit Related Instruments
DebtInstrumentNumberOfCreditRelatedInstruments
16
CY2023Q4 rhe Long Term Debt Maturities Repayments Of Principal In Rolling Year One
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearOne
1944000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
2154000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
8621000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour
1425000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive
1500000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive
36158000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
51802000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
954000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
113000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
50735000
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023 us-gaap Additional Information About Entitys Reportable Segments
AdditionalInformationAboutEntitysReportableSegments
(i) Real Estate segment, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company’s management of three facilities on behalf of third-party owners; and (ii) Healthcare Services segment, which consists of the operation of the Lumber City, LaGrange, Meadowood, Thomasville, Glenvue and the Tara Facilities.
CY2023 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
7069000
CY2022 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
12794000
CY2023 us-gaap Revenues
Revenues
17164000
CY2022 us-gaap Revenues
Revenues
35925000
CY2023 rhe Patient Care Expense
PatientCareExpense
9200000
CY2022 rhe Patient Care Expense
PatientCareExpense
20453000
CY2023 rhe Facility Rent Expense
FacilityRentExpense
594000
CY2022 rhe Facility Rent Expense
FacilityRentExpense
4876000
CY2023 rhe Cost Of Management Fees
CostOfManagementFees
595000
CY2022 rhe Cost Of Management Fees
CostOfManagementFees
619000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2255000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2404000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3976000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4652000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1150000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4916000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1417000
CY2022 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-1436000
CY2023 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
198000
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1974000
CY2023 us-gaap Operating Expenses
OperatingExpenses
17968000
CY2022 us-gaap Operating Expenses
OperatingExpenses
42747000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-804000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-6822000
CY2023 us-gaap Interest Expense
InterestExpense
2751000
CY2022 us-gaap Interest Expense
InterestExpense
2529000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
452000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-333000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2936000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3084000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-45000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-3888000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-6867000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1839028
CY2015Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2015Q2 rhe Common Stock Amount Of Common Dividends In Arrears
CommonStockAmountOfCommonDividendsInArrears
50.00
CY2015Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.055
CY2015Q3 rhe Common Stock Amount Of Common Dividends In Arrears
CommonStockAmountOfCommonDividendsInArrears
55.000
CY2015Q4 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.06
CY2015Q4 rhe Common Stock Amount Of Common Dividends In Arrears
CommonStockAmountOfCommonDividendsInArrears
60.00
CY2015 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.165
CY2015 rhe Common Stock Amount Of Common Dividends In Arrears
CommonStockAmountOfCommonDividendsInArrears
165
CY2017Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2017Q2 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2017Q3 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2017Q4 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2017Q4 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
1912000
CY2017 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2017 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
1912000
CY2018Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2018Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
1912000
CY2018Q2 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2018Q2 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
1912000
CY2018Q3 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.68
CY2018Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
1912000
CY2018Q4 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2018Q4 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2018 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
2.84
CY2018 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
7985000
CY2019Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2019Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2250000
CY2019Q2 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2019Q2 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2019Q3 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2019Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2019Q4 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2019Q4 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2019 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
3.2
CY2019 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
8997000
CY2020Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2020Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2250000
CY2020Q2 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2020Q2 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2020Q3 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2020Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2020Q4 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2020Q4 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2020 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
3.2
CY2020 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
8997000
CY2021Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2021Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2250000
CY2021Q2 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2021Q2 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2021Q3 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2021Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2021Q4 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2021Q4 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2021 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
3.2
CY2021 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
8997000
CY2022Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2022Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2250000
CY2022Q2 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2022Q2 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2022Q3 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2022Q3 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2022Q4 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2022Q4 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2022 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
3.2
CY2022 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
8997000
CY2023Q1 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2023Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2023 us-gaap Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears
PreferredStockPerShareAmountsOfPreferredDividendsInArrears
0.8
CY2023 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
2249000
CY2023 rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
357000
CY2022 rhe Allocated Share Based Compensation Expense Benefit
AllocatedShareBasedCompensationExpenseBenefit
233000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.99
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0395
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4323
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
33000
CY2023 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
14.84
CY2023Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
33000
CY2023Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
14.84
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32000
CY2023 rhe Class Of Warrant Or Right Exercise Price Range Outstanding Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisePriceRangeOutstandingWarrantsWeightedAverageRemainingContractualTerm
P1Y
CY2023 rhe Class Of Warrant And Rights Exercise Price Range Number Of Exercisable Warrants
ClassOfWarrantAndRightsExercisePriceRangeNumberOfExercisableWarrants
32000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2023 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
0
CY2022 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
0
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
385000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
29000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
152000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
192000
CY2023Q4 rhe Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
724000
CY2022Q4 rhe Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
800000
CY2023Q4 rhe Deferred Tax Liabilities Right Of Use Liability
DeferredTaxLiabilitiesRightOfUseLiability
633000
CY2022Q4 rhe Deferred Tax Liabilities Right Of Use Liability
DeferredTaxLiabilitiesRightOfUseLiability
706000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21662000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21127000
CY2023Q4 rhe Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
3581000
CY2022Q4 rhe Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
3315000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
184000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
175000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
15000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
20000
CY2023Q4 rhe Deferred Tax Assets Deferred Expense Interest Expense
DeferredTaxAssetsDeferredExpenseInterestExpense
1831000
CY2022Q4 rhe Deferred Tax Assets Deferred Expense Interest Expense
DeferredTaxAssetsDeferredExpenseInterestExpense
1862000
CY2023Q4 rhe Deferred Tax Assets Net Of Liabilities Gross
DeferredTaxAssetsNetOfLiabilitiesGross
20739000
CY2022Q4 rhe Deferred Tax Assets Net Of Liabilities Gross
DeferredTaxAssetsNetOfLiabilitiesGross
20184000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20739000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20184000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.012
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.022
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.011
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.013
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.134
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.216
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.053
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.003
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company files federal, state and local income tax returns in the U.S. The Company is generally no longer subject to income tax examinations for years prior to fiscal 2018.
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-039414-index-headers.html Edgar Link pending
0000950170-24-039414-index.html Edgar Link pending
0000950170-24-039414.txt Edgar Link pending
0000950170-24-039414-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rhe-20231231.htm Edgar Link pending
rhe-20231231.xsd Edgar Link pending
rhe-ex21_1.htm Edgar Link pending
rhe-ex23_1.htm Edgar Link pending
rhe-ex31_1.htm Edgar Link pending
rhe-ex31_2.htm Edgar Link pending
rhe-ex32_1.htm Edgar Link pending
rhe-ex32_2.htm Edgar Link pending
rhe-ex97_1.htm Edgar Link pending
Show.js Edgar Link pending
rhe-20231231_htm.xml Edgar Link completed